The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
MARS and MAB look like a binary bet on if there is a consumer downturn or not. I think there will be given inflation and fiscal drag and am short MAB. LFL sales aren't keeping pace with food inflation (highest of the lot) so are down in real terms.
I bought this week. Surprised by the weakness. At the same time I'm short FEVR and watching it go to the moon despite profits in reverse gear and still being valued on over 60x earnings. Market makes no sense sometimes
I'd say the main takeaway from today is that Q1 has returned to being rather meaningless in the sheme of annual performance. Pointless inferring much from it though if seasonal weightings mirror 2021, it's actually a very promising start. No retrace in pricing was better than I had expected. I say we're probably not going to have an idea of where we are as a company until the Q3 update.
Need to consider than any cash position is going to bolstered by customer deposits, 10 USD/t I seem to remember being quoted in a previous IMC presentation? This isn't counted as revenue until the product is shipped but it will show on the balance sheet.